No slam dunk for Veklury in COVID-19

2 June 2020

Top-line results from the Phase III SIMPLE trial of Gilead Sciences’ (Nasdaq: GILD) COVID-19 therapy Veklury (remdesivir) show a positive, but not statistically significant impact.

The trial is testing the effect of adding the therapy to standard of care on hospitalized patients with moderate COVID-19 pneumonia.

People in the 5-day Veklury treatment group were 65% more likely to have clinical improvement at Day 11, compared with those in the standard of care group. Those receiving a 10-day treatment course of Veklury also showed a favorable improvement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK